drugset / Trial / NCT01700673
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Phase 2
Completed
25 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To determine the impact of maintenance therapy in patients with MDS/AML in remission.
Timeline
- Start
- 2013-06
- Primary completion
- 2020-06
- Completion
- 2020-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | — |
| Subject | sargramostim | Protein / enzyme biologic | — | — |